These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21385169)

  • 41. High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial.
    Federico M; Clò V; Carella AM
    Leukemia; 1996 Jun; 10 Suppl 2():s69-71. PubMed ID: 8649056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
    Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
    Fernández de Larrea C; Martínez C; Gaya A; López-Guillermo A; Rovira M; Fernández-Avilés F; Lozano M; Bosch F; Esteve J; Nomdedeu B; Montserrat E; Carreras E
    Ann Oncol; 2010 Jun; 21(6):1211-1216. PubMed ID: 19889622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma.
    Di Ianni M; Ballanti S; Iodice G; Reale A; Falzetti F; Minelli O; Serio G; Martelli MF; Dammacco F; Vacca A; Ria R
    Hematology; 2012 Jan; 17(1):23-7. PubMed ID: 22549444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.
    Keller SF; Kelly JL; Sensenig E; Andreozzi J; Oliva J; Rich L; Constine L; Becker M; Phillips G; Liesveld J; Fisher RI; Bernstein SH; Friedberg JW
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):640-7. PubMed ID: 21871246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
    Aurer I; Nemet D; Mitrović Z; Dujmović D; Bašić-Kinda S; Radman I; Sertić D; Šantek F; Kralik M; Dotlić S; Mazić S; Labar B
    Ann Hematol; 2016 Jun; 95(7):1129-36. PubMed ID: 27103009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease.
    Fermé C; Bastion Y; Lepage E; Berger F; Brice P; Morel P; Gabarre J; Nédellec G; Reman O; Chéron N
    Ann Oncol; 1995 Jul; 6(6):543-9. PubMed ID: 8573532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
    Shea TC; Beaven AW; Moore DT; Serody JS; Gabriel DA; Chao N; Gockerman JP; Garcia RA; Rizzieri DA
    Leuk Lymphoma; 2009 May; 50(5):741-8. PubMed ID: 19358012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.
    Fox AM; Dosoretz AP; Mauch PM; Chen YH; Fisher DC; LaCasce AS; Freedman AS; Silver B; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):277-83. PubMed ID: 22019238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
    Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
    Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
    Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
    Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A
    Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.
    Broun ER; Nichols CR; Gize G; Cornetta K; Hromas RA; Schacht B; Einhorn LH
    Cancer; 1997 Apr; 79(8):1605-10. PubMed ID: 9118046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation.
    Magyari F; Simon Z; Barna S; Udvardy M; Váróczy L; Illés Á
    Hematol Oncol; 2012 Jun; 30(2):98-100. PubMed ID: 22034208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
    Fukunaga A; Hyuga M; Iwasaki M; Nakae Y; Kishimoto W; Maesako Y; Arima N
    J Clin Exp Hematop; 2016; 56(1):50-4. PubMed ID: 27334858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
    Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
    Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
    Evens AM; Cilley J; Ortiz T; Gounder M; Hou N; Rademaker A; Miyata S; Catsaros K; Augustyniak C; Bennett CL; Tallman MS; Variakojis D; Winter JN; Gordon LI
    Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
    Biagi JJ; Herbert KE; Smith C; Abdi E; Leahy M; Falkson C; Wolf M; Januszewicz H; Seymour JF; Richards K; Matthews JP; Dale B; Prince HM
    Leuk Lymphoma; 2005 Feb; 46(2):197-206. PubMed ID: 15621802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.